跳至主要内容
临床试验/EUCTR2012-001638-33-CZ
EUCTR2012-001638-33-CZ进行中(未招募)1 期

Cholesterol 7alpha-hydroxylase polymorphism as a predictor cholesterolemia responsiveness

Institute for Clinical and Experimental Medicine0 个研究点目标入组 66 人开始时间: 2012年5月11日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
66

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - sex: males and females
  • - age: 18 - 65 years
  • - confirmation of contraception used (in fertile women)
  • - LDL-cholesterol (calculated) > 3 mmol/l
  • - homozygote for -203A or -203C allele of CYP7A1 gene
  • Sub-study in healthy volunteers:
  • - sex: males
  • - age: 18 - 65 years
  • - BMI < 30 kg/m2
  • - total cholesterol > 5 mmol/l
  • - homozygote for -203A or -203C allele of CYP7A1 gene
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 66
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - triglyceride > 3 mmol/l
  • - pregnancy, breast-feeding
  • - treatment with hypolipidemic drugs and oral anticoagulants
  • - decompensated diabetes mellitus
  • - insulin treatment
  • - serious thyreopathy
  • - presence of another confirmed serious disease that could endanger or disadvantage the patient if included into the trial
  • - hypersensitivity to colesevelam or any of the excipients
  • - intestine or bile duct obstruction, obstipation
  • Sub-study in healthy volunteers:
  • - triglyceride > 3 mmol/l
  • - presence of confirmed serious disease such as ischemic heart disease, diabetes mellitus, thyreopathy, nephrotic syndrome, dysproteinemia and others that could endanger or disadvantage the subject if included into the trial
  • - alcoholism
  • - mental disorders
  • - hypersensitivity to colesevelam or any of the excipients
  • - intestine or bile duct obstruction, obstipation

研究者

发起方
Institute for Clinical and Experimental Medicine

相似试验